During exercise, beta-amino isobutyric acid (L-BAIBA) is produced in skeletal muscle, affecting carbohydrate and fat metabolism in both mammals and humans. 

Joesi M. Krieger’s study aimed to determine the rate and extent to which L-BAIBA appears in human plasma following oral intake. 

For exercise’s health benefits, you can thank a molecule called BAIBA. According to a study published in Cell Metabolism, BAIBA levels — short for beta-aminoisobutyric acid — increase during exercise, and this particular molecule increases fat cell calorie-burning genes. 

Additionally, raising BAIBA levels during exercise was associated with reduced triglycerides, fasting blood sugar, and total cholesterol levels.

As well as improving insulin sensitivity and reducing harmful LDL cholesterol, BAIBA regulates lipid and carbohydrate metabolism to protect against obesity caused by diet. 

Research has shown that BAIBA concentrations are increased with exercise and are inversely related to human metabolic risk factors, making it an excellent candidate for treating metabolic disease, fat loss, and weight loss.

Exercise has positive effects on the metabolism and tissues. For example, l-BAIBA, the exercise-induced muscle factor, plays a critical role in the browning of white fat and insulin resistance. L-BAIBA also functions as a bone-protective factor that prevents osteoclasts from dying from reactive oxygen species (ROS).

Methodology 

The placebo-controlled, randomized crossover study included six males and six females who received placebos (PLA), L-BAIBA at 250 mg, 500 mg, 1,500 mg, and valine at 1,500 mg.

During the fasting overnight (8–10 h), participants drank 8–12 fluid ounces of cold water and consumed their dose. 

After ingestion, venous blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 300 minutes later, and The researchers analyzed a comprehensive metabolic panel and complete blood count at 0 and 300 minutes after consumption.

Researchers calculated the peak concentration (CMax) and area under the curve (AUC) in all variables. There was no significant difference between baseline levels of L-BAIBA between conditions (p = 0.46), but they found that the AUC for B1500 was significantly higher than those for B500, B250, V1500, and PLA. 

Similarly, L-BAIBA CMax for B1500 was significantly higher than all other supplement conditions: B500, B250, V1500, and PLA. 

The AUC and CMax for B500 were significantly higher than those for B250, V1500, and PLA, and BAIBA AUC for B250 was considerably higher than those for V1500 and PLA (p < 0.001). 

Results of the Study

Neither clinically significant changes in blood-based health markers nor adverse events were observed throughout the study protocol. 

Compared to the 1500 mg valine or placebo dose, plasma L-BAIBA concentrations were significantly higher at 250 mg, 500 mg, and 1500 mg during a five-hour measurement window with L-BAIBA doses of 250 mg, 500 mg, and 1500 mg. 

Follow-up studies on resting and exercise metabolism should be conducted to evaluate the effectiveness of L-BAIBA supplementation in normal-weight and overweight individuals. 

Written by